# **Key Information Document ("KID")**



### Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by regulation to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product: GREEN BLUE FUNDS SA SICAV- CGE - TECH CARE FUND Class IB (EUR)

ISIN: LU2701591179

PRIIP Manufacturer: MC Square S.A., 23 Val Fleuri, L 1526 Luxembourg - Call +352 26 92 70 34 82 - www.mcsquare.lu

Competent Authority: The Commission de Surveillance du Secteur Financier is responsible for supervising the manufacturer in

relation to this Key Information Document

Management company: MC Square S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du

Secteur Financier.

KID production date: 31/12/2023

You are about to purchase a product that is not simple and may be difficult to understand.

## What is this product?

## **Type**

This product is a share of a compartment (the "Sub-Fund") of an investment company authorised as an Undertaking for Collective Investment in Transferable Securities (UCITS) under Luxembourg law (the "Fund") in the form of a Société d'Investissement à Capital Variable (S.I.C.A.V).

#### Term

The Fund has no maturity date. Notwithstanding this provision, the Fund may be dissolved at any time by a resolution taken by the general meeting of shareholders.

## **Objectives**

The objective of the Sub-Fund is to provide long-term capital growth by investing primarily in equity securities of small and midcapitalization biotechnology companies worldwide. The Sub-Fund aims to capitalise on investment opportunities in healthcare companies that target attractive addressable markets with strong medical needs and employ disruptive technologies. The Sub-Fund has flexibility to invest up to 20% in China A-shares. The Sub-Fund aims to outperform the SPDR S&P Biotech ETF benchmark in the long term. The Sub-Fund promotes environmental and social characteristics through integrating sustainability risks into investment decisions, though does not have sustainable investment as its primary objective.

#### Intended investor

The Sub-Fund targets eligible, well-informed investors including institutional, professional, and qualified private investors who meet defined expertise, knowledge and minimum investment thresholds. Investors must pass antimoney laundering checks, not be based in the US, and meet capital call deadlines.

### Other information

Depositary: ING Luxembourg S.A.

Dividend income: This class is a capitalisation class meaning that income is reinvested.

Conversion right: The investor may have the right to convert his investment in shares in one sub-fund for shares in the same sub-fund or in another sub-fund. The investor can obtain information about how to convert in the prospectus of the fund. Segregation: The assets and liabilities of a sub-fund are segregated pursuant to the law so that the commitments and liabilities of one sub-fund do not affect the other sub-funds. Additional information: Additional information about the fund, copies of its prospectus, the latest annual and semi-annual report and the latest prices of shares may be obtained free of management from the company www.mcsquare.lu. The prospectus and the periodic reports are prepared for the entire Fund and are available in English. The management company may inform you about other languages in which these documents are available.

## What are the risks and what could I get in return?

## Risk Indicator

1 2 3 4 5 6 7

Lower Risk



The Recommended Holding Period of the product is 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

**Higher Risk** 

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because the Fund is not able to pay you. We have classified this Fund as 6 out of 7, which is a high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the Fund's capacity to pay you. You may lose up to the totality of the amount you have invested in the Fund. Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the

**indicator shown above.** This product does not include any protection from future market performance so you could lose some or all of your investment. If the Fund is not able to pay you what is owed, you could lose your entire investment. The sub-fund is also exposed to the following materially relevant risks that are not included in the summary risk indicator: Liquidity risk, credit risk, counterparty risk, operational risk

# Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate and favourable scenarios shown are illustrations using the worst, average and best performances of the product over the last 10 years, by identifying, depending on the performance scenarios and as defined in Regulation (EU) 2021/2268, all overlapping sub-intervals individually (i) equal in length to the recommended holding period which start or end in each month which are contained within that period of 10 years or (ii) equal or shorter in length to the recommended holding period, but equal to or longer than 1 year, which end at the end of that period of 10 years. Markets could develop very differently in the future.

**Unfavourable**: this type of scenario occurred for an investment between 2018 and 2023. **Moderate**: this type of scenario occurred for an investment between 2018 and 2023. **Favourable**: this type of scenario occurred for an investment between 2018 and 2023. The stress scenario shows what you might get back in extreme market circumstances.

Performance Scenarios			
Example investment: 10,000 EUR (€)		If you exit after 1 year	If you exit after 5 years (recommended holding period)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress scenario	What you might get back after costs	3,611.8	799.62
	Average return each year	-63.88%	-39.66%
Unfavourable scenario	What you might get back after costs	7,447.91	4,541.23
	Average return each year	-25.52%	-14.6%
Moderate scenario	What you might get back after costs	10,703.73	12,568.73
	Average return each year	7.04%	4.68%
Favourable scenario	What you might get back after costs	15,406.72	34,731.1
	Average return each year	54.07%	28.28%

## What happens if MC Square S.A. is unable to pay out?

You may face a financial loss if the Sub-Fund is unable to return your investment due to poor performance. The Investment Manager and the Manufacturer of this product have no obligation itself to pay out since the product design does not contemplate any such payment being made. Any loss you do suffer as a result of actions of the Manager or the Sub-Fund is not covered by an investor compensation or a guarantee scheme.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Cost over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does (where applicable). The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

- In the first year you would get back the amount that you invested (0% annual return). For the other holding period we have assumed the product performs as shown in the moderate scenario;
- 10,000 EUR is invested.

Investment 10,000 EUR (€) Scenarios	If you exit after 1 year	If you exit after 5 years (recommended holding period)
Total costs	66	362.43
Annual cost impact*	0.660%	0.611%

(\*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 5.29% before costs and 4.68% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

## **Composition of costs**

One-off costs upon entry or exit		Annual cost impact if you exit after 1 year		
Entry costs	0.00%, we do not charge an entry fee for this product, but the person selling you the product may do so.	0.00%		
Exit costs	0.00%, we do not charge an exit fee for this product, but the person selling you the product may do so.	0.00%		
Ongoing costs taken each year				
Transaction costs	On average over the last 3 years, based on the value of your investment. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how we buy and sell.	0.440%		
Management fees and other administrative or operating costs	Based on the value of your investment. This is an estimate based on actual costs over the last year	0.220%		
Incidental costs taken under specific conditions				
Performance fees	The Sub-Fund charges a 10% performance fee on the outperformance versus the SPDR S&P Biotech ETF benchmark if the NAV per share exceeds the highest historical NAV per share (the high-watermark) over the last 5 years. The performance fee accrues daily, crystallises annually on December 31, and is paid within 30 days with no cap. Underperformance must be recovered before any performance fee payment.	0%		

# How long should I hold it and can I take money out early?

The recommended investment horizon is at least 5 years. Investors can submit redemption requests to take money out early, but there is a process and timeline to follow: Redemption requests must be received by the deadline of 4pm Luxembourg time 1 business day before the applicable valuation day; Redemption proceeds are paid out in the share class currency no later than 4pm Luxembourg time 2 business days after the applicable valuation day; In case of significant redemptions or lack of asset liquidity, payout may be delayed while asset sales are completed. Investors may receive a partial payout in advance of the final redemption amount. There is a process to follow with deadlines, and payout may be delayed in certain situations. But investors can submit requests to redeem early and take money out before the end of the recommended holding period.

## How can I complain?

Please write to the management company at its registered office (marked for the attention of the Compliance Officer): 23, Val Fleuri, L-1526 Luxembourg, Grand Duchy of Luxembourg or send an email to <a href="mailto:legal@mcsquare.lu">legal@mcsquare.lu</a>.

In all cases, the complainant must clearly indicate his or her contact details (name, address, telephone number or e-mail address) and briefly explain the complaint.

## Other relevant information

This Key Information Document does not contain all information relating to this product. Further information about the Sub-Fund, its prospectus and its latest annual report may be obtained free of charge, in English language, from the Manufacturer, the Manager, or the appointed distributors. The information contained in this Key Information Document does not constitute a recommendation to buy or sell the Product and is no substitute for individual consultation with the investor's bank or advisors. Please see <a href="https://www.mcsquare.lu">www.mcsquare.lu</a> or further details and all documentation related to this investment company.

MC Square S.A. has appointed Cité Gestion S.A. (the "Investment Advisor"), a Swiss independent private bank licensed by the Swiss financial supervisory authority, the FINMA, having its registered office at Rue de la Cité 15-17, 1204 Geneva, Switzerland, registered with the Geneva Register of Commerce under number CHE-114.956.939, further to an investment advisory agreement concluded with effect as of the date of incorporation of the Sub-Fund and in force for an unlimited period of time.

Past performance and performance scenarios: https://kids.mcsquare.lu/reports/LU2701591179